Current Neuro-Oncology
Volume
24 Number 15
15 August 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 15, 15 August
Williamson
D, Schwalbe EC, Hicks D, Aldinger KA, Lindsey JC, Crosier S,
Richardson S, Goddard J, Hill RM, Castle J, Grabovska Y, Hacking
J, Pizer B, Wharton SB, Jacques TS, Joshi A, Bailey S, Clifford
SC.
Medulloblastoma
group 3 and 4 tumors comprise a clinically and biologically
significant expression continuum reflecting human cerebellar
development.
Cell
Rep. 2022 Aug 2;40(5):111162∟.
doi: 10.1016/j.celrep.2022.111162∟.
PMID: 35926460∟.
Laboratory investigation. ˍ
Cho
NS, Hagiwara A, Eldred BSC, Raymond C, Wang C, Sanvito F, Lai A,
Nghiemphu P, Salamon N, Steelman L, Hassan I, Cloughesy TF,
Ellingson BM.
Early
volumetric, perfusion, and diffusion MRI changes after mutant
isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant
gliomas.
Neurooncol
Adv. 2022 Aug 4;4(1):vdac124∟.
doi: 10.1093/noajnl/vdac124∟.
PMID: 36033919∟.
Observational study. ˍ
Pavlova
G, Belyashova A, Savchenko E, Panteleev D, Shamadykova D,
Nikolaeva A, Pavlova S, Revishchin A, Golbin D, Potapov A,
Antipina N, Golanov A.
Reparative
properties of human glioblastoma cells after single exposure to a
wide range of X-ray doses.
Front
Oncol. 2022 Aug 4;12:912741∟.
doi: 10.3389/fonc.2022.912741∟.
PMID: 35992802∟.
Laboratory investigation. ˍ
Reddy R.
A Rare Presentation of
Multifocal Anaplastic Oligodendroglioma.
J
Microsc Ultrastruct. 2022 Aug 4;11(2):115-117∟.
doi: 10.4103/jmau.jmau_126_20?. PMID: 37448825∟.
Case report. ˍ
She
L, Su L, Liu C.
Bevacizumab
combined with re-irradiation in recurrent glioblastoma.
Front
Oncol. 2022 Aug 4;12:961014∟.
doi: 10.3389/fonc.2022.961014∟.
PMID: 36046037∟.
Observational study. ˍ
Taylor
KR, Monje M.
Invasive
glioma cells: The malignant pioneers that follow the
current.
Cell.
2022 Aug 4;185(16):2846-2848∟.
doi: 10.1016/j.cell.2022.06.033∟.
PMID: 35931016∟.
Comment˰
ˍ
Refers
to: Venkataramani
V, et al., Glioblastoma
hijacks neuronal mechanisms for brain invasion.
Cell.
2022 Jul 31;185(16):2899-2917.e31∟.
doi: 10.1016/j.cell.2022.06.054∟.
PMID: 35914528∟.
Laboratory investigation˰
ˍ
Zhou
J, Lai M, Ni Y, Li S, Zhen J, Du F, Zhang X, Song C, Cai L.
Case
Report: Clinicopathological and Genetic Features of IDH-Mutant
Brainstem Glioma in Adults: Report of Five Cases.
Pathol
Oncol Res. 2022 Aug 4;28:1610408∟.
doi: 10.3389/pore.2022.1610408∟.
PMID: 35991838∟.
Case report. ˍ
Merenzon
MA, Gómez Escalante JI, Prost D, Seoane E, Mazzon A, Bilbao
ÉR.
Preoperative
imaging features: Are they useful tools for predicting IDH1
mutation status in gliomas Grades II-IV?
Surg
Neurol Int. 2022 Aug 5;13:332∟.
doi: 10.25259/SNI_373_2022? PMID: 36128131∟.
Observational study. ˍ
Moradi
B, Hamidian Y, Soltanghoraee H, Katouli FS.
Prenatally
detected congenital medulloblastoma.
J
Clin Ultrasound. 2022 Aug 5∟.
doi: 10.1002/jcu.23278∟.
PMID: 35930477∟.
Case report˰ ˍ
Climans
SA, Mason WP, Grunfeld E, Chan K.
Clinical
features of glioma patients who develop pneumocystis pneumonia
with temozolomide chemoradiotherapy.
J
Neurooncol. 2022 Aug 6∟.
doi: 10.1007/s11060-022-04109-1∟.
PMID: 35932358∟.
Observational study˰ ˍ
Cai
X, Chen Z, Chang B, Tu M, Li S, Wang X, Chen M.
Prediction
of BRAF mutation status in glioblastoma multiforme by preoperative
ring enhancement appearances on MRI.
Front
Oncol. 2022 Aug 8;12:937345∟.
doi: 10.3389/fonc.2022.937345∟.
PMID: 36003762∟.
Observational study. ˍ
Sanborn
RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC,
Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A,
Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam
DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler
T.
Safety,
tolerability and efficacy of agonist anti-CD27 antibody
(varlilumab) administered in combination with anti-PD-1
(nivolumab) in advanced solid tumors.
J
Immunother Cancer. 2022 Aug 8;10(8):e005147∟.
doi: 10.1136/jitc-2022-005147∟.
PMID: 35940825∟.
Interventional study. ˍ
Cerretti
G, Cecchin D, Denaro L, Caccese M, Padovan M, Zagonel V, Lombardi
G.
Impressive
response to dabrafenib and trametinib plus silybin in a heavily
pretreated IDH wild-type glioblastoma patient with
BRAFV600E-mutant and SOX2 amplification.
Anticancer
Drugs. 2022 Aug 10∟.
doi: 10.1097/CAD.0000000000001376∟.
PMID: 35946547∟.
Case report˰ ˍ
Schaff
LR, Kushnirsky M, Lin AL, Nandakumar S, Grommes C, Miller AM,
Gavrilovic IT, Nolan C, Pentsova E, Mellinghoff IK, Kaley
TJ.
Combination
Olaparib and Temozolomide for the Treatment of Glioma: A
Retrospective Case Series.
Neurology.
2022 Aug 10∟.
doi: 10.1212/WNL.0000000000201203∟.
PMID: 35948444∟.
Observational study˰ ˍ
Ran
Z, Yang J, Liu Y, Chen X, Ma Z, Wu S, Huang Y, Song Y, Gu Y, Zhao
S, Fa M, Lu J, Chen Q, Cao Z, Li X, Sun S, Yang T.
GlioMarker:
An integrated database for knowledge exploration of diagnostic
biomarkers in gliomas.
Front
Oncol. 2022 Aug 11;12:792055∟.
doi: 10.3389/fonc.2022.792055∟.
PMID: 36081550∟.
Observational study. ˍ
Wood
J, Abdelrazig S, Evseev S, Ortori C, Castellanos-Uribe M, May ST,
Barrett DA, Diksin M, Chakraborty S, Kim DH, Grundy RG, Rahman
R.
Lipoprotein
Deprivation Reveals a Cholesterol-Dependent Therapeutic
Vulnerability in Diffuse Glioma Metabolism.
Cancers
(Basel). 2022 Aug 11;14(16):3873∟.
doi: 10.3390/cancers14163873∟.
PMID: 36010867∟.
Laboratory investigation. ˍ
Lazaridis
L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, Bauer S,
Schildhaus HU, Sure U, Keyvani K, Kleinschnitz C, Stuschke M,
Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M.
Precision
neuro-oncology: a pilot analysis of personalized treatment in
recurrent glioma.
J
Cancer Res Clin Oncol. 2022 Aug 12∟.
doi: 10.1007/s00432-022-04050-w∟.
PMID: 35953681∟.
Observational study. ˍ
Simanjuntak
KAT, Al Fauzi A, Christi AY, Budiono PS, Susilo RI, Haq IBI,
Suroto NS, Fauziah D, Djatisoesanto W.
Clear-cell
renal cell carcinoma and glioblastoma multiforme coexistence:
Double primary malignancy, does it have a causal
relationship?
Surg
Neurol Int. 2022 Aug 12;13:361∟.
doi: 10.25259/SNI_598_2022∟.
PMID: 36128116∟.
Case report. ˍ
*
El-Abtah
ME, Talati P, Fu M, Chun B, Clark P, Peters A, Ranasinghe A, He J,
Rapalino O, Batchelor TT, Gilberto Gonzalez R, Curry WT, Dietrich
J, Gerstner ER, Ratai EM.
Magnetic
resonance spectroscopy outperforms perfusion in distinguishing
between pseudoprogression and disease progression in patients with
glioblastoma.
Neurooncol
Adv. 2022 Aug 15;4(1):vdac128∟.
doi: 10.1093/noajnl/vdac128∟.
PMID: 36071927∟.
Observational study. ˍ
Kawauchi
D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Omura T, Yoshida
A, Kubo Y, Igaki H, Ichimura K, Narita Y.
Early
Diagnosis and Surgical Intervention Within 3 Weeks From Symptom
Onset Are Associated With Prolonged Survival of Patients With
Glioblastoma.
Neurosurgery.
2022 Aug 15∟.
doi: 10.1227/neu.0000000000002096∟.
PMID: 35951724∟.
Observational study. ˍ
Wang
L, Wang Z, Liang Z, Li G, Duan S, Xi Y.
Short-
and long-term efficacy of sustained-release chemotherapy in tumor
bed interstitium combined with surgical resection for recurrent
malignant glioma.
Am
J Transl Res. 2022 Aug 15;14(8):5669-5676∟.
PMID: 36105035∟.
Observational study. ˍ